Trust the Science
A great deal of test data and anecdotal evidence indicates that hemp hybrid extract can provide animals with symptomatic relief from a range of medical conditions. Until now, however, there has been no rigorous scientific veterinary research.
Colorado State University College of Veterinary Medicine and Biomedical Sciences (CSU) is the first the institution in the nation to conduct veterinary clinical trials with hemp hybrid oil extract. These studies are sponsored by Applied Basic Science Corporation, the maker of C.H.O. Pet Tincture, and will drastically alter the field of veterinary medicine and be a force for change in today’s attitudes for best practices in veterinary medicine.
Our Partners: Pioneers in Their Fields of Expertise
C.H.O. Pet Tincture was developed in partnership with some of the country’s leading experts in the medical use of hemp-hybrid oil extract as well as in veterinary neurology and science.
Stephanie McGrath, DVM is an Assistant Professor at Colorado State University College of Veterinary Medicine and Biomedical Sciences and lead researcher on multiple clinical trials using C.H.O. Pet Tincture. Board-certified in veterinary neurosurgery and neurology, Dr. McGrath is an expert in seizure disorders, inflammatory brain disease, and spinal cord injury.
Alan Shackelford, MD, is one of the nation’s leading medical experts on the medical use of hemp-hybrid oil extract. Based at Amarimed of Denver, Colorado, he is an advisor to numerous companies, agencies and governments worldwide. Dr. Shackelford conducted his post-graduate medical training at the major teaching hospitals of the Harvard Medical School, including three fellowships.
Science Based and Proven Safe
Applied Basic Science Corporation (ABSC), the maker of C.H.O. Pet Tincture, sponsored CSU’s Phase 1 Study to investigate the safety of specified combinations and delivery methods of our hemp-hybrid oil extract in dogs. Results confirming that dogs tolerated clinical doses of the compound found in C.H.O. Pet Tincture without adverse effects were presented at a conference at the Institute of Cannabis Research Conference at CSU-Pueblo on April 29, 2017 and will be published in 2018.
Happening Now: Efficacy Studies for Epilepsy and Osteoarthritis
Multiple Phase 2 studies are currently underway at CSU using the compound found in C.H.O. Pet Tincture. Research results are expected to be published in 2018.
Informing AVMA’s Policy on C.H.O. Pet Tincture
The results of the clinical trials using the compound found in C.H.O. Pet Tincture are being closely watched by the American Veterinary Medical Association (AVMA) and will help inform their policies on its use.
American Kennel Club Drug-Resistant Epilepsy Study
ABSC is the exclusive supplier of the oil to the American Kennel Club Canine Health Foundation trial studying drug-resistant epilepsy.